| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2024-02-14 | AVENIR CORP | Cytosorbents Corp | 3,051,402 | 6.9% | EDGAR |
| SC 13G | 2024-02-14 | Granahan Investment Management, LLC | Cytosorbents Corp | 3,618,143 | 6.9% | EDGAR |
| SC 13G | 2024-01-08 | Skylands Capital, LLC | Cytosorbents Corp | 3,254,213 | 7.3% | EDGAR |
| SC 13G/A | 2023-02-14 | AVENIR CORP | Cytosorbents Corp | 2,447,089 | 5.6% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Cytosorbents Corp | 1,956,828 | 4.5% | EDGAR |
| SC 13G | 2023-02-07 | Skylands Capital, LLC | Cytosorbents Corp | 2,542,091 | 5.8% | EDGAR |
| SC 13G | 2022-08-11 | AVENIR CORP | Cytosorbents Corp | 2,187,782 | 5.0% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | Cytosorbents Corp | 744,958 | 1.7% | EDGAR |
| SC 13G/A | 2022-06-28 | AVENIR CORP | Cytosorbents Corp | 2,156,833 | 5.0% | EDGAR |
| SC 13G | 2022-04-25 | AVENIR CORP | Cytosorbents Corp | 2,177,146 | 5.0% | EDGAR |
| SC 13G/A | 2022-02-09 | VANGUARD GROUP INC | Cytosorbents Corp | 2,209,165 | 5.1% | EDGAR |
| SC 13G/A | 2022-02-03 | BlackRock Inc. | Cytosorbents Corp | 2,631,210 | 6.1% | EDGAR |
| SC 13G/A | 2022-01-07 | AVENIR CORP | Cytosorbents Corp | 2,088,071 | 4.8% | EDGAR |
| SC 13G | 2021-12-13 | AVENIR CORP | Cytosorbents Corp | 2,244,335 | 5.2% | EDGAR |
| SC 13G | 2021-02-10 | VANGUARD GROUP INC | Cytosorbents Corp | 2,221,606 | 5.2% | EDGAR |
| SC 13G/A | 2021-01-29 | BlackRock Inc. | Cytosorbents Corp | 2,762,288 | 6.4% | EDGAR |
| SC 13G/A | 2020-02-05 | BlackRock Inc. | Cytosorbents Corp | 2,059,602 | 6.4% | EDGAR |
| SC 13G | 2019-02-08 | BlackRock Inc. | Cytosorbents Corp | 1,985,640 | 6.3% | EDGAR |
| SC 13G | 2006-11-20 | CHASSMAN MARGIE | MedaSorb Technologies CORP | 4,795,000 | 19.6% | EDGAR |
| SC 13D | 2006-07-24 | Montiel Guillermina Vega | GILDER ENTERPRISES INC | 5,052,456 | 20.9% | EDGAR |